We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer's (PFE) Shares Drop on Rating Downgrade by JP Morgan
Read MoreHide Full Article
Pfizer Inc. (PFE - Free Report) shares fell almost 0.9% on Dec 11 after JPMorgan Chase & Co. (JPM - Free Report) downgrading its rating on the company to “neutral”, as reported in a CNBC article.
JP Morgan downgraded Pfizer as it expects share price growth of the latter to decelerate following a 22% rise so far this year. The rating company states that although Pfizer is focused on re-accelerating growth of its top and bottom line beyond 2020, it is trading on par with its peers, suggesting that the growth factor has already been factored in the price. Any further momentum in stock price is likely to be fueled by “additional pipeline success or positive new launch momentum”, largely expected beyond 2020. Thus, JP Morgan has assumed a wait and see policy for the company.
Pfizer’s stock has increased 21.5% so far this year compared with the industry's gain of 7.4%.
We remind investors that the company’s top line is being impacted by loss of exclusivity of several drugs including Celebrex, Lipitor and Norvasc among others. Pfizer is also set to lose patent cover for several other drugs over the next few years, which includes Lyrica and Chantix. Moreover, Pristiq and Viagra lost patent exclusivity in 2017 and are facing generic competition.
Meanwhile, other pharma companies are looking to get approval for generic version of the company’s key products Xtandi and Xeljanz. In fact, loss of exclusivities hurt 2017 sales by $2.1 billion and is expected to hurt revenues by about $2 billion in each of the next three years (through 2020).
However, Pfizer is committed to bring newer drugs in the market and is investing heavily in its pipeline, which includes treatment for oncology, metabolic disease and cardiovascular risks, rare diseases, immunology, inflammation and vaccines as well as immuno-oncology. The company expects to gain approval for approximately 25 to 30 drugs by 2022, which includes about 15 products with blockbuster potential. Successful development of its pipeline is likely to offset the impact of generic competition though it will take a few years to happen.
Pfizer also has several licensing deals and collaborative agreements related to development of its pipeline. These include deals with Merck (MRK - Free Report) for diabetes medicine, Bristol-Myers (BMY - Free Report) for blood thinner drug, Eliquis, and Novartis for non-alcoholic steatohepatitis (“NASH”).
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Pfizer's (PFE) Shares Drop on Rating Downgrade by JP Morgan
Pfizer Inc. (PFE - Free Report) shares fell almost 0.9% on Dec 11 after JPMorgan Chase & Co. (JPM - Free Report) downgrading its rating on the company to “neutral”, as reported in a CNBC article.
JP Morgan downgraded Pfizer as it expects share price growth of the latter to decelerate following a 22% rise so far this year. The rating company states that although Pfizer is focused on re-accelerating growth of its top and bottom line beyond 2020, it is trading on par with its peers, suggesting that the growth factor has already been factored in the price. Any further momentum in stock price is likely to be fueled by “additional pipeline success or positive new launch momentum”, largely expected beyond 2020. Thus, JP Morgan has assumed a wait and see policy for the company.
Pfizer’s stock has increased 21.5% so far this year compared with the industry's gain of 7.4%.
We remind investors that the company’s top line is being impacted by loss of exclusivity of several drugs including Celebrex, Lipitor and Norvasc among others. Pfizer is also set to lose patent cover for several other drugs over the next few years, which includes Lyrica and Chantix. Moreover, Pristiq and Viagra lost patent exclusivity in 2017 and are facing generic competition.
Meanwhile, other pharma companies are looking to get approval for generic version of the company’s key products Xtandi and Xeljanz. In fact, loss of exclusivities hurt 2017 sales by $2.1 billion and is expected to hurt revenues by about $2 billion in each of the next three years (through 2020).
However, Pfizer is committed to bring newer drugs in the market and is investing heavily in its pipeline, which includes treatment for oncology, metabolic disease and cardiovascular risks, rare diseases, immunology, inflammation and vaccines as well as immuno-oncology. The company expects to gain approval for approximately 25 to 30 drugs by 2022, which includes about 15 products with blockbuster potential. Successful development of its pipeline is likely to offset the impact of generic competition though it will take a few years to happen.
Pfizer also has several licensing deals and collaborative agreements related to development of its pipeline. These include deals with Merck (MRK - Free Report) for diabetes medicine, Bristol-Myers (BMY - Free Report) for blood thinner drug, Eliquis, and Novartis for non-alcoholic steatohepatitis (“NASH”).
Pfizer Inc. Price
Pfizer Inc. Price | Pfizer Inc. Quote
Zacks Rank
Pfizer currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>